Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Pembrolizumab + Chemotherapy for Recurrent Laryngeal/Hypopharyngeal SCC
NCT06793761Phase 2Not yet recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in laryngeal squamous cell carcinoma (LSCC), hypopharyngeal squamous cell carcinoma (HSCC), sponsored by Beijing Tongren Hospital. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
03
Conditions
laryngeal squamous cell carcinoma (LSCC)hypopharyngeal squamous cell carcinoma (HSCC)
Beyond the preview
Go deeper on NCT06793761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06793761.